ARCA biopharma, Inc. (NasdaqCM:ABIO) will look for acquisitions. ARCA biopharma has announced a public offering of aggregate of shares of its common stock, to raise gross proceeds of $2,499,876. ARCA biopharma currently intends to use the net proceeds from the sale of the securities for general corporate purposes, including clinical trials, potential in-licensing agreements, research and development expenses and general and administrative expenses. ARCA biopharma may also use a portion of the net proceeds to invest in or acquire businesses or technologies that ARCA biopharma believe are complementary to their own, although ARCA biopharma have no current plans, commitments or agreements with respect to any acquisitions as of the date of the prospectus supplement.